PSA levels and PSA doubling time (PSADT) prior to radiotherapy predict outcomes following rescue radiation therapy for men with prostate cancer.
Zvi Symon, MD, and his colleagues at Chaim Sheba Medical Center in Tel Hashomer, Israel, studied 50 prostate cancer patients who failed treatment with rescue radiation. Their median pre-radiotherapy PSA was 1.2 ng/mL and the median dose of radiation of 66.6 Gy. The median follow-up was 39.6 months.
Overall the estimated three-year failure-free survival rate was 54%. A pre-radiotherapy PSA greater than 1 ng/mL and seminal vesicle involvement increased the risk of rescue failure 6.2 and 7.3 times, respectively, the investigators reported in the American Journal of Clinical Oncology (2006;29:446-450).